BacoCure
Bacterial Products for Treatment of Non-muscle Invasive Bladder Cancer
Company Overview
Snapshot
Founded in February 2018 by Ofer Mandelboim, Yutkin Vladimir, and Gili (Gilad) Bachrach, BacoCure operates with 1–10 employees. The company has secured funding across one disclosed round from one investor. In February 2018, BacoCure received seed funding, marking a key milestone in its development of a novel immuno-oncology drug for bladder cancer.
Business overview
BacoCure is a Health Tech & Life Sciences company focused on developing bacterial products for the treatment of non-muscle invasive bladder cancer. Its core product is a mutated and inactivated uropathogenic bacteria designed for local therapy, demonstrating anti-tumor effects with a differentiated mechanism of action and improved safety profile compared to existing treatments. The company operates in the Pharmaceuticals sector, serving global markets and targeting patients within the healthcare and life sciences industries.
Log in to access full profile ›Company Intelligence Q&A
- What is BacoCure's primary focus?
- BacoCure is developing a novel bacterial product for the local therapy of patients with non-muscle invasive bladder cancer.
- When was BacoCure founded?
- BacoCure was founded in February 2018.
- Who are the founders of BacoCure?
- The founders of BacoCure are Ofer Mandelboim, Yutkin Vladimir, and Gili (Gilad) Bachrach.
- What is the current development stage of BacoCure's lead product?
- BacoCure's lead product, a novel mutated and inactivated uropathogenic bacteria for non-muscle invasive bladder cancer, is at an advanced preclinical development stage as of March 2021.